- Title: India begins human trials of coronavirus vaccine
- Date: 17th July 2020
- Summary: ROHTAK, HARYANA, INDIA (JULY 17, 2020) (ANI - NO USE INDIA) PEOPLE WALKING OUTSIDE PANDIT BHAGWAT DAYAL SHARMA POST GRADUATE INSTITUTE OF MEDICAL SCIENCES BUILDING/CARS SIGNBOARD READING (English): PT.BD. SHARMA POST GRADUATE INSTITUTE OF MEDICAL SCIENCES" VARIOUS OF PEOPLE WALKING IN CORRIDORS INSIDE HOSPITAL VICE-CHANCELLOR, PANDIT BHAGWAT DAYAL SHARMA POST GRADUATE INSTITUTE OF MEDICAL SCIENCES O. P. KALRA (CENTER) AND OTHERS SITTING KALRA SPEAKING (SOUNDBITE) (Hindi) VICE-CHANCELLOR, PANDIT BHAGWAT DAYAL SHARMA POST GRADUATE INSTITUTE OF MEDICAL SCIENCES, O. P. KALRA, SAYING: "Today we enrolled three subjects for human trial (of coronavirus vaccine) and it was inspected that they tolerated this vaccine in a good manner and there was no adverse effect on them." OFFICIALS SEATED
- Embargoed: 31st July 2020 16:00
- Keywords: India Rohtak coronavirus health human trial vaccine
- Location: ROHTAK, HARYANA, INDIA
- City: ROHTAK, HARYANA, INDIA
- Country: India
- Topics: Health/Medicine
- Reuters ID: LVA001CN78SB3
- Aspect Ratio: 16:9
- Story Text: India began human trials of coronavirus vaccine in India's northern Rohtak city on Friday (July 17).
The trials come on the day the number of coronavirus cases crossed one million in India.
Three subjects were administered the vaccine at Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences who showed no adverse effects, said Vice-Chancellor, Pandit Bhagwat Dayal Sharma Post Graduate Institute Of Medical Sciences, O. P. Kalra.
Bharat Biotech's COVID-19 vaccine had been approved for human trials earlier. It is India's first domestic candidate to get the green light from the government's drug regulator as cases surge in a country with more than 1.3 billion people.
Covaxin was developed and manufactured in Bharat Biotech's facility at Genome Valley in Hyderabad, India.
The Drug Controller General of India had approved the company's application to conduct a Phase I and II clinical trial of Covaxin, which was developed along with the Indian Council of Medical Research's National Institute of Virology.
After 14 days a second dose would be given to the patients after which the adverse effects of the vaccine, if any would be studied along with how much of antibody level is produced.
India has the third-highest total in the world behind Brazil and the United States with a total of 1003832 cases.
More than 25,000 people have died from the disease since the first case in India in January - low when compared to countries with similar numbers of cases. But experts fear hospitals in the densely populated nation will be unable to cope with a steep rise in cases.
No vaccine has yet been approved for commercial use against the illness caused by the new coronavirus, but over a dozen vaccines from more than a 100 candidates globally are being tested in humans.
- Copyright Holder: ANI (India)
- Copyright Notice: (c) Copyright Thomson Reuters 2020. Open For Restrictions - http://about.reuters.com/fulllegal.asp
- Usage Terms/Restrictions: None